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Agmatine-Containing Poly(amidoamine)s as a Novel Class of Antiviral
Macromolecules: Structural Properties and In Vitro Evaluation of
Infectivity Inhibition
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Poly(amidoamine)s (PAAs) are multifunctional tert-amine polymers endowed with high structural versatility. Here we report on
the screening of a minilibrary of PAAs against a panel of viruses. The PAA AGMA1 showed antiviral activity against herpes sim-
plex virus, human cytomegalovirus, human papillomavirus 16, and respiratory syncytial virus but not against human rotavirus
and vesicular stomatitis virus. The results suggest the contribution of both a polycationic nature and side guanidine groups in
imparting antiviral activity.
The development of antiviral molecules usually focuses on ei-ther preventing virus entry into the host cell or inhibiting virus
replication following host infection. The first strategy may be
based on antiviral polyanionic polymers capable of competitively
blocking the interaction between viral proteins and cell surface
heparan sulfate proteoglycans (HSPGs), which are exploited as
attachment receptors bymany viruses (1–4). Notwithstanding the
large number of studies demonstrating their efficacy in preclinical
models, polyanionic polymers somehow failed in clinical trials
(5). Unlike polyanions, polycationic polymers have been less in-
vestigated as antiviral compounds. In principle, polycations may
act as antivirals by electrostatically interacting either with the neg-
atively charged cell membrane or with the envelope of lipid-en-
veloped viruses, thus preventing virus adsorption onto cell sur-
faces, or by directly inactivating the virus particle. In this context,
it was shown that the cationic poly(acrylic ester) Eudragit E 100,
endowed with a membrane-destabilizing activity, exerts antiviral
activity against a panel of lipid-enveloped viruses (6, 7). Another
study demonstrated that polyethylenimine, a cationic polymer
able to condenseDNAandmediate gene transfer intomammalian
cells, inhibits infection by human cytomegalovirus (HCMV) and
human papillomavirus (HPV), a lipid-enveloped virus and a non-
enveloped virus, respectively (8).
Poly(amidoamine)s (PAAs) are multifunctional tert-amine
polymers endowed with high structural versatility, obtained by
Michael polyaddition of amines and bis-acrylamides (9). The re-
peating units of PAAs can be designed to be reminiscent of pep-
tides. For instance, an amphoteric, prevailingly cationic PAA
named AGMA1 is a polymer mimic of the arg-gly-glu peptide
(RGD) (10, 11).
In the search for new antiviral compounds, a minilibrary of
PAAswas screened against a panel of seven viruses, namely, herpes
simplex virus type 1 and 2 (HSV-1, HSV-2), HCMV, HPV-16,
human respiratory syncytial virus (RSV), human rotavirus
(HRV), and vesicular stomatitis virus (VSV), chosen as represen-
tative of different virus characteristics, such as the presence or
absence of lipid envelope, a DNA or RNA genome, and HSPG
dependency for virus attachment (12–16).
The minilibrary included three water-soluble PAAs, ISA1,
ISA23, and AGMA1, whose structures are reported in Fig. 1. The
copolymeric PAA ISA1 (17), containing two randomly distributed
repeating units present in equal amounts, and the homopolymeric
PAAs ISA23 (17, 18) and AGMA1 (10) were prepared as previ-
ously reported. AGMA1 fractions with different average molecu-
lar weights were obtained by ultrafiltration against water using
membranes with different nominal molecular weight cutoffs, as
previously described (11). ISA1 is weakly cationic, but ISA23 and
AGMA1 are amphoteric, with isoelectric points of 5.2 and
10.3. As reported in Table 1, at pH 7.4, these PAAs have, respec-
tively, 0.55, 0.55, and 0.55 average charges per unit. For
ISA1, the reported value corresponds to the ionization degree of
its tert-amine groups, with no other ionizable groups being pres-
ent. For ISA23 and AGMA1, the reported figures correspond to
the excess negative-over-positive charges and vice versa, that is,
respectively,1 plus 0.45 and1 plus 1.55 per unit. Thus, at pH
7.4, the overall cationic charges of ISA1 and AGMA1 are superfi-
cially similar, but a deeper investigation reveals that their real
charge distributions are different.
Antiviral assayswere performedby infecting cellmonolayers in
the presence of serial dilutions of compounds for 2 h at 37°C to
generate dose-response curves and a selectivity profile of the
PAAs’ antiviral spectra. The inocula were subsequently washed
out and replaced with culture medium containing the same con-
centration of compounds. The effect on HSV and VSV infections
was evaluated by a standard plaque reduction assay on preseeded
Vero cells in 24-well plates (10  104 cells) infected with 300
PFU/well of clinical isolates of HSV-1 and HSV-2 (19) and VSV
serotype Indiana; after incubation for 24 h (HSV-2 andVSV) or 48
h (HSV-1) at 37°C in 5% CO2, cells were fixed and stained with
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0.1% crystal violet in 20% ethanol and viral plaques were counted.
The mean plaque count for each drug concentration was ex-
pressed as a percentage of the mean plaque count of the control.
In HCMV and RSV inhibition assays, infected cells were fixed
and subjected to virus-specific immunostaining as described pre-
viously (20, 21). In these assays, cells were preseeded at a density of
6 103/well in 96-well plates. Hep-2 cells were infected with RSV
strain A2 (60 PFU/well), whereas HELF cells were infected with
HCMV strain AD169 (24 PFU/well). Three days (RSV) or 5 days
(HCMV) postinfection, immunostained viral plaques were mi-
croscopically counted.
HPV inhibition assays were performed on preplated 293TT
cells (2 104/well in 96-well plates) using HPV-16 secreted alka-
line phosphatase (SEAP) pseudoviruses (PsV) at the final concen-
tration of 1 ng/ml liter1; 3 days postinfection, the SEAP content
in the clarified supernatant was determined as previously de-
scribed (22). Plasmids used for PsV production were kindly pro-
vided by J. Schiller (NCI, Bethesda,MD,USA). Antiviral assays for
rotavirus were carried out on preplatedMA104 cells (1 104/well
in 96-well plates) using human rotavirus strain Wa (200 PFU/
well). After 16 h, viral foci were determined by indirect immuno-
staining (22).
The endpoints of the assays were the effective compound con-
centration that reduced the viral plaque/focus formation or SEAP
activity by 50% (EC50) in comparison to that in the untreated
control. The F test was used to compare logEC50s, and two-way
analysis of variance was used to analyze the significance between
percentages of infection at the same doses of different compounds
not able to generate EC50s. P values of 0.05 were considered
statistically significant. The EC50swere calculated and all statistical
analyses were performed by using the program PRISM 4 (Graph-
Pad Software, San Diego, CA, USA). The viability of cells pre-
seeded in 96-well plates was determined under identical culture
conditions in antiviral assays (i.e., cell density and time of incuba-
tion with compounds) using a CellTiter 96 proliferation assay kit
(Promega, Madison, WI, USA). The 50% cytotoxic concentra-
tions (CC50) were determined using Prism software, and the se-
lectivity index (SI) was calculated by dividing theCC50 by the EC50
(19). All data were generated from duplicate wells in at least three
independent experiments. Heparin was included in the study as a
positive control, being a known inhibitor of HSPG-dependent
viruses (e.g., HSV-1,HSV-2,HCMV, RSV, andHPV-16) (23–26).
As expected, heparin blocked infection by HSPG-dependent vi-
ruses but not that by VSV and HRV, which are not dependent on
HSPG (Table 2).
Data reported in Table 2 prompt the following observations.
The PAA antiviral effect was not a consequence of cytotoxicity,
since none of the screened compounds significantly reduced cell
viability at any concentration tested (i.e., up to 300g/ml); there-
FIG 1 Chemical structures of the AGMA1, ISA1, and ISA23 repeating units.
TABLE 1 Physicochemical characteristics of PAAs
Polymer M n
a
Net avg charge
per unit at pH 7.4
Avg negative
charge per
unit at pH 7.4
Avg positive
charge per
unit at pH 7.4
Polydisperse 10,100 0.55 1.00 1.55
AGMA1
AGMA14 4,500 0.55 1.00 1.55
AGMA17 7,800 0.55 1.00 1.55
AGMA120 20,500 0.55 1.00 1.55
ISA1 13,600 0.55 0.0 0.55
ISA23 16,500 0.55 1.00 0.45
a M¯n, number average molecular weight.
M¯n

i1
n
NiMi

i1
n
Ni
where Ni is the number of macromolecules containing i repeating units and Mi is the
weight of macromolecules containing i repeating units.
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fore, their CC50 values may be considered to be higher than 300
g/ml in all the cell lines tested.
Polydisperse AGMA1 strongly inhibited infections by HSV-1,
HSV-2, HCMV, and HPV-16, generating dose-response curves
with EC50s of 3.04, 5.34, 0.76, and 0.54 g/ml, respectively. Inter-
estingly, AGMA1 was significantly more active than heparin
against HSV-1 and HPV-16 infections, whereas it was as active as
heparin against HCMV infection (P 0.05). In contrast, polydis-
perse AGMA1 was inactive against RSV, HRV, and VSV.
To evaluate the influence of molecular weight on antiviral
potency, three additional linear AGMA1 fractions were pre-
pared, namely, AGMA14 (M n, 4,500), AGMA17 (M n, 7,800), and
AGMA120 (M n, 20,500) (Table 1). As depicted in Table 2, frac-
tions with lower and higher molecular weights than that of poly-
disperse AGMA1 (M n, 10,100) maintained inhibitory activity
against HSV-1, HSV-2, HCMV, and HPV-16 although to differ-
ent extents. AGMA14 showed a stronger anti-HSV-1 activity than
that of heparin, and all fractions were more active than heparin
against HPV-16 infection (P  0.05). No statistically significant
differences were observed between the EC50 of heparin and the
EC50s of AGMA14 against HSV-2 and HCMV infections and be-
tween the EC50 of heparin and the EC50 of AGMA120 against
HSV-1 infection.
Unlike polydisperse AGMA1, AGMA14, AGMA17, and
AGMA120 were also active against RSV, with EC50 values of 8.87,
7.44, and 1.37 g/ml, respectively. Both of the polydisperse
AGMA1 and AGMA1 fractions failed to display any significant
inhibitory effect against HRV and VSV. The antiviral activity of
AGMA1 seems not to be dependent on its molecular weight for
HSV-1, HSV-2, HCMV, and HPV-16; instead, there is a clear
relationship between the AGMA1 fractions’ sizes and their anti-
RSV potency. Explaining why polydisperse AGMA1 did not exert
a detectable anti-RSV activity while all of the size fractions did
demands further investigation.
Polymers do not consist of a singlemolecular species but rather
of families of homologous species differing in their numbers of
repeating units. Therefore, it is considered inappropriate to adopt
the molar concept describing their properties. Nevertheless, to
compare activities across compounds, Table 3 shows the EC50s of
AGMA1 fractions andheparin expressed in termsofmolarity instead
ofg/ml, considering theaveragemolecularweight reported inTable
1. It was not possible to convert the average molecular mass of poly-
disperse AGMA1 in terms of molar equivalents, since its molecular
mass isnotunivocallydefined. Interestingly, the relationshipbetween
the AGMA1 fractions’ sizes and their anti-RSV potency, reported in
the text where data are expressed in terms of g/ml, is preserved.
Furthermore, AGMA17 and AGMA120 preserved a higher anti-
HPV-16 activity than that of heparin (P  0.05). In contrast, the
antiviral activity ofAGMA14 in termsofmolarity is lower than that in
terms ofg/ml; its activity is similar to that of heparin againstHSV-1
and HPV-16 infections and is lower than that of heparin against
HSV-2 andHCMV (P 0.05). This behaviormight be ascribed to a
greater rigidity of the polymer with the lowest molecular weight. Be-
cause all of the polymers are polyelectrolytes, it is necessary to take
into account that the charge density markedly affects the dynamic
rheological properties, the flexibility, and the chain entanglements.
Increased polymer charge density results in intermolecular electro-
static repulsion and increased polymer solubility.
Next, to investigate whether the activity of AGMA1was specif-
ically due to the structure of its repeating unit, the antiviral activ-
ities of ISA1 and ISA23 were assessed. Overall, while AGMA1 was
active against HSV-1, HSV-2, HCMV, RSV, and HPV-16 infec-
tion, ISA1 was active only against HCMV and RSV, with a lower
activity than that of heparin, and was as active as heparin against
TABLE 2 Antiviral activities of PAAs and heparina
Compound Virus EC50 (g/ml) (95% CI) CC50 (g/ml) SI
AGMA1 HSV-1 3.04 (1.75–5.28) 300 98.7
HSV-2 5.34 (1.85–15.4) 300 56.2
HCMV 0.76 (0.40–1.47) 300 395
HPV-16 0.54 (0.53–0.55) 300 556
RSV 100 300 NA
HRV 100 300 NA
VSV 100 300 NA
AGMA14 HSV-1 1.93 (1.43–2.61) 300 155
HSV-2 1.35 (0.57–3.17) 300 222
HCMV 0.39 (0.11–1.30) 300 769
HPV-16 0.92 (0.53–1.58) 300 326
RSV 8.87 (6.51–12.1) 300 33.8
HRV 100 300 NA
VSV 100 300 NA
AGMA17 HSV-1 17.0 (11.4–25.4) 300 17.6
HSV-2 4.80 (3.13–7.35) 300 62.5
HCMV 4.45 (3.28–5.90) 300 67.4
HPV-16 0.79 (0.44–1.44) 300 380
RSV 7.44 (3.11–17.8) 300 40.3
HRV 100 300 NA
VSV 100 300 NA
AGMA120 HSV-1 5.10 (3.21–8.10) 300 58.8
HSV-2 2.82 (1.72–4.64) 300 106
HCMV 4.14 (2.50–6.86) 300 72.5
HPV-16 0.72 (0.50–1.06) 300 417
RSV 1.37 (1.11–1.68) 300 219
HRV 100 300 NA
VSV 100 300 NA
ISA1 HSV-1 100 300 NA
HSV-2 100 300 NA
HCMV 1.26 (0.79–2.00) 300 238
HPV-16 3.55 (1.97–6.40) 300 84.5
RSV 9.54 (5.51–16.5) 300 31.4
HRV 100 300 NA
VSV 100 300 NA
ISA23 HSV-1 100 300 NA
HSV-2 100 300 NA
HCMV 100 300 NA
HPV-16 100 300 NA
RSV 100 300 NA
HRV 100 300 NA
VSV 100 300 NA
Heparin HSV-1 5.22 (4.22–6.45) 300 57.5
HSV-2 0.67 (0.39–1.18) 300 448
HCMV 0.38 (0.24–0.64) 300 789
HPV-16 2.88 (1.81–4.57) 300 104
RSV 0.05 (0.04–0.06) 300 6,000
HRV 100 300 NA
VSV 100 300 NA
a EC50, 50% effective concentration; 95% CI, 95% confidence interval; CC50, 50%
cytotoxic concentration; SI, selectivity index; NA, not assessable.
Antiviral Properties of PAAs
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HPV-16 (P 0.05). ISA23was inactive in all cases. At pH7.4, both
AGMA1 and ISA1 are positively charged, whereas ISA23 is nega-
tively charged. It is known that polycationic polymers establish
ionic interactions with the cell surface HSPG (27, 28), a feature
that may impart antiviral activity to these compounds. This fea-
ture, along with the finding that the active PAAs have the same
antiviral activity spectrum as heparin, supports the hypothesis
that PAAs may exert their antiviral action, at least in part, by
interacting with HSPG, thus preventing virus attachment. How-
ever, notwithstanding the fact that AGMA1 and ISA1 carry the
same density of positive charges, i.e., 0.55, AGMA1 showed a
greater activity for HSV-1, HSV-2, and HPV-16. This may be due
to the different real charge distributions on the macromolecules
and to their side guanidine groups reinforcing membrane inter-
actions, according to theirwell-known chaotropic properties (29).
In contrast, the guanidine side group does not seem to be neces-
sary for the anti-HCMV activity. Furthermore, a different chain
entanglement might explain the different activity of AGMA1 with
respect to that of RSV. Overall, these results provide a starting
point to tailor a macromolecule with enhanced antiviral activity
against a selected virus. Future work will be focused on narrowing
the molecular mass distribution of PAA samples to assist in pre-
clinical development.
Studies are ongoing to elucidate the mechanisms of action of
the active PAAs and their antiviral potential and biocompatibility
profile in preclinical models.
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